Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. TG Therapeutics, Inc.
  6. Summary
    TGTX   US88322Q1085

TG THERAPEUTICS, INC.

(TGTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
6.04(c) 6.5(c) 6.47(c) 6.82(c) 6.1(c) Last
2 957 425 3 047 446 1 895 399 2 690 378 2 396 295 Volume
+5.78% +7.62% -0.46% +5.41% -10.56% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 22,9 M - -
Net income 2022 -247 M - -
Net cash position 2022 11,7 M - -
P/E ratio 2022 -3,47x
Yield 2022 -
Sales 2023 114 M - -
Net income 2023 -221 M - -
Net cash position 2023 41,9 M - -
P/E ratio 2023 -4,15x
Yield 2023 -
Capitalization 811 M 811 M -
EV / Sales 2022 34,9x
EV / Sales 2023 6,78x
Nbr of Employees 286
Free-Float 91,9%
More Financials
Company
TG Therapeutics, Inc. (TG) is a fully integrated, commercial stage biopharmaceutical company, which is focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. Its pipeline candidates include TG-1501 (Cosibelimab), TG-1701 (BTK inhibitor), TG-1801 (anti-CD47/anti-CD19 bispecific monoclonal antibody). Its UKONIQ (umbralisib) is developed for the... 
Read more
More about the company
Ratings of TG Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about TG THERAPEUTICS, INC.
05/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Th..
PR
05/11TG THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/10TG THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/10TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
04/27TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthal..
AQ
04/26TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthal..
AQ
04/25SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Th..
PR
04/19B. Riley Lowers TG Therapeutics' PT to $23 from $35, Says Exit from Oncology 'Disappoin..
MT
04/18TG Therapeutics Down More Than 20% After Dropping Biologics License Application for Leu..
MT
04/18Top Midday Decliners
MT
04/18TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients..
AQ
04/18SECTOR UPDATE : Health Care Stocks Modestly Lower Pre-Bell Monday
MT
04/18Wall Street Set for Narrow Losses Amid Rising Bond Yields
MT
04/18SECTOR UPDATE : Health Care
MT
04/18TRANSCRIPT : TG Therapeutics, Inc. - Special Call
CI
More news
News in other languages on TG THERAPEUTICS, INC.
05/10TG Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2..
04/18TG Therapeutics en baisse de plus de 20 % après l'abandon de la demande de licence biol..
04/18MISE À JOUR SECTORIELLE : Soins de santé
04/18TG Therapeutics abandonne une demande de licence de produits biologiques pour un traite..
04/15TG Therapeutics, Inc. annonce le retrait volontaire de la BLA/sNDA pour U2 pour traiter..
More news
Analyst Recommendations on TG THERAPEUTICS, INC.
More recommendations
Chart TG THERAPEUTICS, INC.
Duration : Period :
TG Therapeutics, Inc. Technical Analysis Chart | TGTX | US88322Q1085 | MarketScreener
Technical analysis trends TG THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 6,10 $
Average target price 19,63 $
Spread / Average Target 222%
EPS Revisions
Managers and Directors
Michael Sean Weiss Chairman, President & Chief Executive Officer
Sean A. Power Chief Financial Officer, Secretary & Treasurer
Owen A. O'Connor Chief Scientific Officer
Laurence N. Charney Lead Independent Director
Yann Echelard Independent Director
Sector and Competitors
1st jan.Capi. (M$)
TG THERAPEUTICS, INC.-67.89%811
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524